Axa’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Axa’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,700	Closed	-$245K	–	1190
2023 Q1	$245K	Buy	+2,700	New	+$158K	﹤0.01%	1049
2022 Q4	–	Sell	-12,600	Closed	-$317K	–	1237
2022 Q3	$317K	Buy	+12,600	New	+$349K	﹤0.01%	1030
2020 Q3	–	Sell	-2,900	Closed	-$452K	–	1371
2020 Q2	$452K	Sell	2,900 -2,400	-45%	-$365K	﹤0.01%	1081
2020 Q1	$765K	Buy	+5,300	New	+$1.02M	﹤0.01%	899
2019 Q2	–	Sell	-4,800	Closed	-$410K	–	1381
2019 Q1	$410K	Buy	+4,800	New	+$398K	﹤0.01%	1133

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's RETA Position: Q2 2023 in Review

Axa sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 2,700 shares — an estimated $245K sold.

Axa first reported a position in RETA in Q1 2019 and held it in 5 quarters. The position peaked at $765K in Q1 2020. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Axa reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Axa sold 2,700 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $245K.
Axa first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 5 quarters.
Axa's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $765K in Q1 2020.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.